Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has resumed. Moreover, this is a particularly busy start to the week for those of you scrambling about at JPM, which is essentially a Woodstock for pharmaceutical executives and finance types. Here is a tip for coping — make frequent stops for a cup of stimulation. We, in fact, are hoisting one right now. Meanwhile, the world keeps spinning, so to keep you up to date, we have gathered a fresh menu of tidbits. Hope you have a productive day, wherever you are, and do keep in touch. …
The American Academy of Pediatrics for the first time recommended physicians offer weight-loss drugs for children with obesity, aiming to take early action against an increasingly common condition linked to a host of health problems, The Wall Street Journal reports. Children 12 or older who are obese should be offered medications for weight loss alongside lifestyle and behavioral counseling, says the association, which also recommended doctors offer to refer severely obese children 13 or older to surgeons to assess whether they would be good candidates for bariatric surgery, and that pediatricians should screen obese children for high cholesterol, diabetes, and hypertension.
What should be a triumphant return to the global biotech industry’s biggest annual event, “JPM Week,” after a two-year hiatus is turning as gloomy as Bay Area weather, with industry executives forecasting economic troubles in the year ahead, STAT says. More than 100 biotech and pharma executives, investors, and other insiders were asked about the state of the sector heading into 2023 and on the eve of the J.P. Morgan Healthcare Conference in San Francisco. The biggest takeaway: Nearly 70% of respondents said financing — raising venture capital, launching an IPO, or selling additional stock to further fund R&D and other operations — will be a headwind in 2023.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect